Scorpion Therapeutics is a clinical-stage precision oncology biotechnology company founded in 2020 and headquartered in Boston, Massachusetts. It pursued what it called Precision Oncology 2.0 — integrating target discovery, medicinal chemistry and translational medicine to produce mutant-selective small-molecule cancer drugs — led by STX-478, an oral mutant-selective PI3K-alpha inhibitor in Phase 1/2 trials for breast cancer and other advanced solid tumors, and STX-721, a covalent EGFR/HER2 exon 20 inhibitor. In January 2025 Eli Lilly agreed to acquire Scorpion and its PI3K-alpha program in a transaction valued at up to $2.5 billion, with the non-PI3K-alpha pipeline and staff spun into a separate independent company. Scorpion is a drug developer, not a software vendor: it publishes no API, SDK, developer portal or machine-readable specification, and its own domain now redirects to the acquirer's announcement.
Scorpion Therapeutics is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Pharmaceuticals, Oncology, and Precision Medicine.
Regulatory Posture applies to this provider. Its tags matched the
Health regime, so
Regulatory Posture carries 15 points of the composite.
If this regime is wrong for your business, say so on your
provider repo — the
applicability map is public and we will correct it.
Create-or-Update Ergonomics could not be measured. We hold no machine-readable contract for
this provider to read, so there is nothing to measure a write surface against. Excluded rather than scored zero:
never-measured and measured-empty are different facts. Publishing an OpenAPI is what makes this facet — and
several others — scorable at all.
The six quality facets above are damped to 85 points between them,
because the conditional facet above carries the other
15. That is why each facet's contribution is shown against a damped
maximum: raising a quality facet moves the composite by 85% of its nominal
weight, not 100%. The full arithmetic is at apis.io/rating/.
aid: scorpion-therapeutics
name: Scorpion Therapeutics
description: 'Scorpion Therapeutics is a clinical-stage precision oncology biotechnology company founded in 2020 and headquartered
in Boston, Massachusetts. It pursued what it called Precision Oncology 2.0 — integrating target discovery, medicinal chemistry
and translational medicine to produce mutant-selective small-molecule cancer drugs — led by STX-478, an oral mutant-selective
PI3K-alpha inhibitor in Phase 1/2 trials for breast cancer and other advanced solid tumors, and STX-721, a covalent EGFR/HER2
exon 20 inhibitor. In January 2025 Eli Lilly agreed to acquire Scorpion and its PI3K-alpha program in a transaction valued
at up to $2.5 billion, with the non-PI3K-alpha pipeline and staff spun into a separate independent company. Scorpion is
a drug developer, not a software vendor: it publishes no API, SDK, developer portal or machine-readable specification, and
its own domain now redirects to the acquirer''s announcement.'
deliveryModel:
model: unknown
open_source: false
commercial: false
callable_host: false
label: Delivery model not determined — needs a product licence on record
confidence: low
source:
- none
generated: '2026-08-28'
method: derived
accessModel:
pricing: unknown
onboarding: unknown
trial: false
try_now: false
public: false
label: Unknown
confidence: low
source:
- security
generated: '2026-09-02'
method: derived
image: https://avatars.githubusercontent.com/u/73207155?v=4
url: https://raw.githubusercontent.com/api-evangelist/scorpion-therapeutics/refs/heads/main/apis.yml
x-type: company
x-source: harvest:secondary-market
x-tier: stub
x-tier-reason: harvest
specificationVersion: '0.23'
created: '2026-08-05'
modified: '2026-08-05'
tags:
- Company
- Biotechnology
- Pharmaceuticals
- Oncology
- Precision Medicine
- Drug Discovery
- Life Sciences
- Clinical Research
apis: []
maintainers:
- FN: Kin Lane
email: kin@apievangelist.com
- FN: APIs.json
email: info@apis.io
common:
- type: DomainSecurity
url: security/scorpion-therapeutics-domain-security.yml
- type: Website
url: https://www.scorpiontx.com/
- type: GitHubOrganization
url: https://github.com/scorpiontx
- type: LinkedIn
url: https://www.linkedin.com/company/scorpiontherapeutics
- type: Press
url: https://investor.lilly.com/news-releases/news-release-details/lilly-acquire-scorpion-therapeutics-mutant-selective-pi3ka
x-enrichment:
date: '2026-08-05'
status: minimal
artifacts_added: 1
pass: local-v1
x-coverage:
state: none
reason: defunct
detail: Scorpion's own site no longer serves the company — https://www.scorpiontx.com/ 302-redirects every request to Eli
Lilly's January 2025 acquisition press release, and the only first-party technical surface left is a four-repo GitHub
org of computational-chemistry forks and an STX-721 molecular-dynamics data-availability README, with no API, SDK or spec
anywhere.
evidence:
- url: https://www.scorpiontx.com/
status: 302
- url: https://www.scorpiontx.com/openapi.json
status: 404
- url: https://www.scorpiontx.com/llms.txt
status: 404
- url: https://www.scorpiontx.com/.well-known/agent-card.json
status: 403
- url: https://api.github.com/orgs/scorpiontx
status: 200
checked: '2026-08-05'
Discovery needs no key. Ratings and market analysis are Pro.
Get an API key
Free tier, no form to fill in. Signing in shares your email address with us — we
store it to create your key and to recognise you if you sign in with another
provider. See our Privacy Policy and
Terms.
Kin Score
How this is scored →